Financials in USD. Standardized financial statements.
A compact view of how Epigenomics AG turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $23,990 | $0 | $339,227 | $485,000 | $6.20M | $842,000 | $1.13M | $1.53M | $1.86M | $4.20M |
| Revenue Growth? | 0.0% | -100.0% | -30.1% | -92.2% | +636.7% | -25.2% | -26.6% | -17.8% | -55.6% | 0.0% |
| Cost of Revenue? | $0 | $11,995 | $56,912 | $120,000 | $136,000 | $145,000 | $253,000 | $440,000 | $246,000 | $1.63M |
| Gross Profit? | $0 | -$11,995 | $282,315 | $365,000 | $6.07M | $697,000 | $872,000 | $1.09M | $1.62M | $2.57M |
| Gross Margin? | 0.0% | 0.0% | +83.2% | +75.3% | +97.8% | +82.8% | +77.5% | +71.3% | +86.8% | +61.1% |
| Operating Expenses? | $359,864 | $1.13M | $4.78M | $12.42M | $8.42M | $12.32M | $15.54M | $13.99M | $11.91M | $14.88M |
| Operating Income? | -$335,873 | -$1.14M | -$4.18M | -$12.05M | -$2.35M | -$11.63M | -$14.67M | -$12.89M | -$10.29M | -$12.31M |
| EBITDA? | -$335,873 | -$3.34M | -$3.61M | -$11.22M | -$1.94M | -$11.07M | -$13.99M | -$12.57M | -$9.93M | -$11.94M |
| Income Before Tax | -$313,882 | -$3.35M | -$4.46M | -$12.10M | -$2.41M | -$11.66M | -$14.57M | -$13.43M | -$10.45M | -$12.30M |
| Income Tax Expense | $0 | $0 | $0 | -$77,000 | $18,000 | $23,000 | $2.45M | -$738,000 | -$214,000 | -$1.14M |
| Net Income? | -$313,882 | -$3.35M | -$4.46M | -$12.02M | -$2.43M | -$11.69M | -$17.02M | -$12.69M | -$10.23M | -$11.16M |
| EPS? | $-0.36 | $-3.82 | $-5.23 | $-14.78 | $-4.33 | $-39.67 | $-71.65 | $-14.74 | $-12.59 | $-15.69 |
| Diluted EPS? | $-0.36 | $-3.82 | $-5.23 | $-14.78 | $-4.33 | $-39.67 | $-71.65 | $-14.74 | $-12.59 | $-15.69 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality